Effector CD4+ T-cell subsets in Takayasu arteritis-differences between the peripheral blood and the aorta.

大动脉炎中效应 CD4+ T 细胞亚群——外周血与主动脉的差异

阅读:10
作者:Savioli Bruna, Torquato Heron Fernandes Vieira, Paredes-Gamero Edgar Julian, Franco Andréia Fabiana do Vale, Gigek Carolina de Oliveira, Artigiani Neto Ricardo, de Souza Alexandre Wagner Silva
Takayasu arteritis (TAK) is a granulomatous vasculitis that affects large arteries. T cells are important in TAK pathophysiology as these cells orchestrate granulomatous infiltration in arteries. This study aims to evaluate effector CD4+ T cells in the peripheral blood and the aortic wall of TAK patients and to analyze associations with disease activity and therapy. We performed a longitudinal study including 30 TAK patients and 30 controls. CD3+ T cells, CD3+CD4- T cells, CD4+ T cells, and Th1, Th2, and Th17 cells were evaluated in peripheral blood by flow cytometry, and the expression of CD4, CD8, Tbet, GATA-3, and RORγT was analyzed in the aorta of six patients by immunohistochemistry. TAK patients presented lower CD3+ T cells and CD4+ T cells (P†=†0.031 and P†=†0.039, respectively) than controls. Patients with active disease and those in remission had higher proportions of Th17 cells than controls (P†=†0.016 and P†=†0.004, respectively). Therapy for TAK did not result in significant differences concerning CD4+ effector T-cell subpopulations. Disease duration correlated with the number and percentage of Th2 cells (rho†=†-0.610 and rho†=†-0.463, respectively) and with Th17 cells (rho†=†-0.365 and rho†=†-0.568). In the aorta, the expression of CD8 was higher than CD4, whereas GATA-3, Tbet, and RORγT were expressed in this order of frequency. In conclusion, TAK patients present an increased Th17 response in the peripheral blood regardless of disease activity, whereas in the aortic tissue CD8 cells and the Th2 response were predominant.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。